Armata Pharmaceuticals (ARMP) Assets Average (2014 - 2026)
Armata Pharmaceuticals (ARMP) posted Assets Average of $73.3 million for Q1 2026, down 11.85% sequentially from $83.2 million in Q4 2025, and down 15.55% YoY from $86.8 million in Q1 2025.
Armata Pharmaceuticals (ARMP) Assets Average (2014 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Assets Average for 13 years, with the latest figure at $73.3 million in Q1 2026.
- Quarterly Assets Average fell 15.55% year-over-year to $73.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.3 million (down 15.55% YoY) and the FY2025 annual result came in at $81.7 million, down 11.62% from the prior year.
- Assets Average retreated to $73.3 million in Q1 2026 per ARMP's latest filing, from $83.2 million in the prior quarter.
- Over five years, Assets Average peaked at $114.3 million in Q2 2024 and troughed at $73.3 million in Q1 2026.
- A 5-year average of $96.2 million and a median of $96.9 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average surged 113.15% in 2022, then fell 26.51% in 2025.
- Over 5 years, Assets Average stood at $94.4 million in 2022, then climbed by 11.87% to $105.6 million in 2023, then declined by 12.53% to $92.3 million in 2024, then decreased by 9.9% to $83.2 million in 2025, then dropped by 11.85% to $73.3 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $73.3 million, $83.2 million, and $85.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Armata Pharmaceuticals | 162.98 Mn | 138.98 Mn | - | 79.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.88 Mn |
| Mar 31, 2026 | 73.34 Mn |
| Dec 31, 2025 | 83.20 Mn |
| Sep 30, 2025 | 85.15 Mn |
| Jun 30, 2025 | 84.02 Mn |
| Mar 31, 2025 | 86.84 Mn |
| Dec 31, 2024 | 92.34 Mn |
| Sep 30, 2024 | 103.28 Mn |
| Jun 30, 2024 | 114.33 Mn |
| Mar 31, 2024 | 109.36 Mn |
| Dec 31, 2023 | 105.56 Mn |
| Sep 30, 2023 | 106.99 Mn |
| Jun 30, 2023 | 105.00 Mn |
| Mar 31, 2023 | 102.31 Mn |
| Dec 31, 2022 | 94.36 Mn |
| Sep 30, 2022 | 96.93 Mn |
| Jun 30, 2022 | 104.37 Mn |
| Mar 31, 2022 | 88.77 Mn |
| Dec 31, 2021 | 56.22 Mn |
| Sep 30, 2021 | 45.48 Mn |